English
Language31 languages
EnglishEnglishDeutschGermanالعربيةArabicFrançaisFrenchEspañolSpanishPortuguês (Brasil)Brazilian PortugueseItalianoItalian日本語Japanese한국어KoreanРусскийRussianTürkçeTurkishفارسیPersian (Farsi)עבריתHebrewҚазақшаKazakhPolskiPolishNederlandsDutchRomânăRomanianČeštinaCzechΕλληνικάGreekMagyarHungarianBahasa IndonesiaIndonesianहिन्दीHindiاردوUrduBahasa MelayuMalayไทยThaiУкраїнськаUkrainianO‘zbekchaUzbekTiếng ViệtVietnamese繁體中文Traditional ChineseDanskDanishSvenskaSwedish

Supported languages are prioritized from the country mix of past inquiries. If you would like another language, please send us feedback.

Recent Confirmed OrdersLast 7 days
Australia2 gTirzepatide 100 mg · CagriSema 20 mg · BPC-157 10 mg · TB-500 5 mg · Melanotan II 10 mg · PT-141 10 mg · Bacteriostatic Water 3 ml
View all

Longevity research

Epithalon

AEDG tetrapeptide research reference · human evidence is limited and concentrated

Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COACAS 307297-39-8RUO
Research statusLimited cellular, animal and small human evidence from a concentrated research lineage; no FDA-approved drug; laboratory Research Use Only reference context · supplied material is RUO
Supplied formLinear tetrapeptide; H-Ala-Glu-Asp-Gly-OH (AEDG)
Lead time7–14 days
Epithalon — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA
Epithalon — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • Research applications include AEDG identity and impurity-method development, telomerase and telomere-maintenance assays, comparison of normal and cancer cell responses, histone or gene-expression hypotheses, retinal models and critical replication of a concentrated evidence base
  • Reported lifespan, sleep, retinal or anti-ageing outcomes are study-specific observations, not product benefits.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
307297-39-8
Formula
C14H22N4O9
Molecular weight
390.35 g/mol
Appearance
Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA
Purity
Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COA
Storage
Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, container and any prepared-solution hold time require evidence for the exact AEDG form, counterion, matrix and concentration; no universal 2–8 °C, -20 °C, 30-day or bacteriostatic-water rule applies.
MOQ
On request
Lead time
7–14 days
PubChem CID 219042

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Epithalon

Epitalon, also spelled Epithalon, is the sequence-defined tetrapeptide H-Ala-Glu-Asp-Gly-OH (AEDG). PubChem CID 219042 lists formula C₁₄H₂₂N₄O₉, molecular weight 390.35 g/mol and CAS 307297-39-8. It was developed in the Khavinson research lineage as a synthetic peptide associated with the heterogeneous bovine pineal extract Epithalamin; the two materials are not analytically or evidentially interchangeable. Most human and animal literature comes from that lineage. A 2025 independent cell study adds laboratory evidence but received a correction and does not establish human longevity or safety. The May 12, 2026 FDA briefing states that the nominations of Epitalon free base and Epitalon acetate were withdrawn, that FDA is evaluating them on its own initiative and that the available criteria weigh against Section 503A Bulks List placement. PCAC discussion is scheduled for July 24, 2026; scheduling is not approval or a final FDA determination.

  • Sequence and identity qualification; stability-indicating analytics; controlled telomerase, telomere, ALT, histone, gene-expression and retinal-model research; and independent replication of lineage-concentrated findings
  • These are research applications, not clinical indications or anti-ageing claims.

Mechanism context

The question the literature is testing

In-vitro work reports hTERT expression and telomerase-associated telomere extension in selected normal cells. The corrected 2025 study reported telomere extension through hTERT/telomerase upregulation in IBR.3 and HMEC normal cells and through alternative lengthening of telomeres (ALT) in 21NT and BT474 breast-cancer cells. Histone-binding, gene-expression, melatonin and antioxidant pathways remain model-dependent hypotheses. These findings do not establish a human mechanism, clinical benefit or safety.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context
Routes reported in sources
No administration route applies
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • Not for human or veterinary use
  • In its 2026 briefing, FDA found no pharmacokinetic data and no clinical studies assessing human safety for Epitalon-related bulk substances
  • Absence of reports in searched passive databases does not establish safety
  • Telomere extension in breast-cancer cell lines is an in-vitro mechanistic observation, not proof of human carcinogenicity, but it underscores the absence of an adequate clinical safety assessment
  • Follow the released-lot SDS and institutional controls.

Interactions reported in the literature

  • No controlled combination or patient drug-interaction programme was identified
  • Pairings with melatonin, Thymalin, NAD+ precursors, growth-hormone-related peptides, BPC-157, Semax, Selank or Cortexin are not validated compatibility, synergy or safety guidance.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Epithalon factory batch COAs

Epithalon 10 mg Factory batch COA protected previewEpithalon10 mg · WHJLP-EPI10-260707-A
Epithalon 50 mg Factory batch COA protected previewEpithalon50 mg · WHJLP-EPI50-260707-A
Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

  • Require exact AEDG sequence and termini, free-base or salt assignment, counterion, theoretical and observed high-resolution intact mass, orthogonal sequence evidence where appropriate, stability-indicating HPLC purity and impurity profile, quantitative peptide content, water/counterion/residual solvents and lot-specific stability
  • Sterility, bacterial endotoxin and particulate claims require separate released-lot tests
  • Appearance, solution clarity or a generic ≥99% area result cannot establish identity, content or suitability.
Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
AEDG-10MG10 mg10 vials
AEDG-50MG50 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, container and any prepared-solution hold time require evidence for the exact AEDG form, counterion, matrix and concentration; no universal 2–8 °C, -20 °C, 30-day or bacteriostatic-water rule applies.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • Identity: PubChem CID 219042. Cellular evidence: PubMed PMID 12937682; the 2025 Biogerontology study, PMID 40908429 and PMCID PMC12411320; and its November 2025 correction, PMID 41240216 and PMCID PMC12619744. Human retinal context: PMID 12195242, interpreted within its limited reporting and single-lineage setting. Regulatory status and evidence gaps: FDA briefing dated May 12, 2026 and the official July 23–24, 2026 PCAC meeting page; FDA also records the former retinitis-pigmentosa orphan designation as withdrawn or revoked and not approved.
  1. 01

    Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells

    Bulletin of Experimental Biology and Medicine · 2003 · peer-reviewed original research (in vitro)

    Open source
  2. 02

    Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity

    Biogerontology · 2025 · peer-reviewed original research (in vitro)

    Open source
  3. 03

    Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties

    International Journal of Molecular Sciences · 2025 · peer-reviewed review article

    Open source
  4. 04

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging

    Frontiers in Aging · 2026 · peer-reviewed review article

    Open source
  5. 05

    Peptides of pineal gland and thymus prolong human life

    Neuroendocrinology Letters · 2003 · clinical follow-up study (non-blinded, non-placebo-controlled)

    Open source
  6. 06

    Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up

    Bulletin of Experimental Biology and Medicine · 2011 · clinical follow-up study (non-blinded)

    Open source
  7. 07

    Evaluation of Epitalon-Related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances List

    U.S. Food and Drug Administration / Pharmacy Compounding Advisory Committee · 2026 · official regulatory briefing document

    Open source

Product FAQ

Questions buyers ask about Epithalon

Are Epitalon, Epithalon, Epithalamin and N-acetyl Epitalon the same material?+

Epitalon and Epithalon are spelling variants used for the sequence-defined AEDG tetrapeptide in PubChem CID 219042. Epithalamin is a heterogeneous bovine pineal extract, not purified AEDG. N-acetyl Epitalon has an added acetyl group and a different formula and mass. Evidence, safety and release specifications cannot be transferred among these materials without exact identity confirmation.

What do the human and 2025 cell studies establish?+

Human reports are few, small and concentrated in one research lineage; the 2002 retinitis-pigmentosa publication reports clinical observations but does not establish a modern replicated treatment standard. A 2025 independent in-vitro study reported hTERT/telomerase-associated telomere extension in normal cell lines and ALT-associated extension in breast-cancer cell lines, then received a correction to Figures 1–3. Cell findings do not establish human longevity, anti-ageing efficacy or safety.

What should a buyer verify for an AEDG lot?+

Require the exact N-to-C AEDG sequence and termini, free-base or salt assignment, counterion, high-resolution intact mass, orthogonal sequence evidence where appropriate, stability-indicating HPLC with an impurity profile, quantitative peptide content, water, residual solvents and lot-specific stability. Sterility and bacterial endotoxin are separate tests. A trade name, white powder or nominal purity percentage cannot distinguish AEDG from an acetylated form, another short peptide or an extract.

Related research materials

Compare adjacent molecules and documentation needs.

Full catalog
Mitochondrial research

MOTS-c (Human)

Native human 16-residue mitochondrial-derived research peptide · evidence remains predominantly preclinical

Purity
Lot-specific · Batch COA
CAS
1627580-64-6
Latest batch COA available on request
Longevity research

FOXO4-DRI

46-residue D-retro-inverso FOXO4–p53 interaction research peptide · cell and mouse evidence only

Purity
Lot-specific · Batch COA
CAS
2460055-10-9
Latest batch COA available on request
Longevity research

PNC-27

p53-HDM2-binding · penetratin-fused research peptide

Purity
Target ≥ 99.0% · Batch COA
CAS
1159861-00-3
Latest batch COA available on request